Comparative Pharmacology
Head-to-head clinical analysis: AGAMREE versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGAMREE versus CORTIFOAM.
AGAMREE vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid receptor agonist; modulates transcription via glucocorticoid response elements, suppressing inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and immune cell activity.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Initial dose: 600 mg (6 tablets of 100 mg or 3 tablets of 200 mg) orally once daily for 4 weeks, then 400 mg orally once daily for weeks 5-8; total treatment duration 8 weeks.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3 hours in adults. The half-life may be prolonged in patients with hepatic impairment.
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites. Renal excretion of metabolites accounts for about 60%.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid